Join Dr. Malika Elhage Hassan tomorrow 11/21 at 10:55am during Session 8 of the VEITHsymposium Associate Faculty Podium presentations as she presents an abstract detailing the outcomes of the on-the-table technique for treating acute intermediate-risk Pulmonary Embolism with the BASHIR? Endovascular Catheter. #VEITH2024 Thrombolex.com
关于我们
Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmaco-mechanical catheter-directed thrombolysis (PM-CDT) in patients who suffer from arterial and venous thromboembolic (A&VTE) conditions. The Company is currently marketing seven (7) different FDA-cleared devices that are all based on the BASHIR? Endovascular Catheter platform technology.
- 网站
-
https://www.thrombolex.com
Thrombolex, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Doylestown,Pennsylvania
- 类型
- 私人持股
- 创立
- 2016
地点
-
主要
75 Britain Dr
US,Pennsylvania,Doylestown,18901
Thrombolex, Inc.员工
动态
-
Results from the RESCUE-II trial show a breakthrough in treating intermediate high-risk pulmonary embolism. Utilizing the BASHIR? Endovascular Catheter, this protocol achieved all clinical endpoints with a 4mg dose of r-tPA in each pulmonary artery while completing the case on-the-table. Patients experienced a significant improvement in RV/LV ratio and reduction in pulmonary artery occlusion, with no adverse events. #Thrombolex Thrombolex.com
-
Visiting the VEITHsymposium this week in NYC? Don’t miss the presentation by Dr. Eric Secemsky tomorrow 11/19 at 8:45am about the BASHIR? Endovascular Catheter’s unique and differentiated on-the-table approach to treating Pulmonary Embolism. #VEITH24
-
Congratulations to the Cath Lab team at Vanderbilt University Medical Center on successfully completing their first single-session PE intervention with the Bashir catheter. This novel approach allowed the patient to bypass the ICU and receive only 8mg of tPA in a procedure that lasted less than twenty-five minutes. I'm incredibly proud to work with this fantastic group. #pe #bashir #pulmonaryembolism #thrombolex
-
To treat acute PE, you need a therapy that is safe, reliable, and easy to use. The BASHIR? Endovascular Catheter is clinically proven to have superior safety and efficacy while demonstrating some of the best clinical and safety data amongst contemporary PE trials. Learn more at Thrombolex.com. #Thrombolex
-
Another successful VEINS Conference! A special thank you to Dr. Patrick Muck for his thorough review of preliminary data from the RESCUE-II Study. The RESCUE-II Study highlights the effectiveness of single-session pharmacomechanical lysis (PML) without the need for post-procedural thrombolytic infusion when treating pulmonary embolism. We are grateful for the opportunity to connect with top clinicians, share insights, and discuss our latest advancements. #Thrombolex Thrombolex.com
-
A special thank you to the VEINS team for hosting such an engaging and informative event. We appreciated the opportunity to learn from eachother and look forward to next year. #VEINS #Thrombolex Thrombolex.com
-
Join Dr. Patrick Muck during VEINS 2024 today at 10:05am for an in-depth review of single-session outcomes using the BASHIR? Endovascular Catheter for the treatment of Pulmonary Embolism (PE). #VEINS #Thrombolex Thrombolex.com
-
Join us at VEINS 2024 in Las Vegas to learn more about our innovative solutions for treating thromboembolic diseases with clinically proven safety and efficacy. #VEINS #Thrombolex Thrombolex.com